Key facts
- This page summarizes Theodore R. Schroeder's Form 4 filing for Nabriva Therapeutics plc.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 31 Jan 2023, 19:55.
Theodore R. Schroeder - 29 Jan 2023 Form 4 Insider Report for Nabriva Therapeutics plc
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 29 Jan 2023
- Net transaction value
- -$646
- SEC form
- 4
- Accepted by SEC
- 31 Jan 2023, 19:55:00 UTC
- Prior SEC filing
- 10 Jan 2023
- Next SEC filing
- 23 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ J. Christopher Naftzger, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Theodore R. Schroeder filed Form 4 for Nabriva Therapeutics plc on 31 Jan 2023.
Change
- Previous filing in this sequence was filed on 10 Jan 2023.
- Current net transaction value: -$646.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NBRV
transaction
Ordinary Shares
Tax liability
- Transaction value
- $646
- Shares
- -431
- Change %
- -3.5%
- Price
- $1.50
- Shares after
- 11,989
- Date
- 29 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.